Navigation Links
Vasogen Announces First Quarter 2008 Results
Date:4/3/2008

MISSISSAUGA, ON, April 3 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ:VSGN; TSX:VAS), today reported the results of operations for the three months ended February 29, 2008. All dollar amounts referenced herein are in Canadian dollars unless otherwise noted.

At February 29, 2008, our cash and cash equivalents totaled $19.9 million, compared with $23.5 million at November 30, 2007.

We incurred a net loss for the three months ended February 29, 2008, of $5.3 million, or $0.24 per common share, compared with a net loss of $7.7 million, or $0.47 per common share for the same period in 2007. A key driver of this decrease was a $1.6 million reduction in expenses resulting from the repayment of the senior convertible notes in April 2007, and lower infrastructure and other support costs driven by lower employee numbers in 2008.

For the three months ended February 29, 2008, research and development expenses decreased to $2.8 million from $3.0 million for the comparable period in 2007. During the first quarter of 2008, these costs were incurred for the initial commercialization of Celacade in Europe and for preparations for ACCLAIM II, a study designed to evaluate the Celacade technology for the treatment of patients with NYHA Class II heart failure.

General and administration expenses were $2.7 million for the three months ended February 29, 2008, compared to $3.6 million for the same period in 2007 as a result of lower employee numbers.

Highlights

- In January, preclinical findings demonstrating that VP025, the lead

candidate from our VP series of drugs, provides a significant

neuroprotective effect in a model of Parkinson's disease were

published in the European Jou
'/>"/>

SOURCE Vasogen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation
2. Vasogen Announces Third Quarter 2007 Results
3. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
4. Vasogen Provides an Update on ACCLAIM-II Preparations
5. Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure
6. Vasogen to Conduct Year-end 2007 Conference Call
7. Vasogen Announces 2007 Year-End Results
8. The Lancet Publishes Vasogens ACCLAIM Results
9. Vasogens Research Published in European Journal of Neuroscience
10. Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel
11. Vasogen Provides Update on ACCLAIM II Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014  ( www.competitivehealth.com ) — Competitive ... medical bill review and advocacy service, has signed an ... WellCard Savings discount health services marketplace. 63% ... more than they expected to pay. As part of ... costs, WellCard Savings is pleased to offer medical bill ...
(Date:12/22/2014)... 22, 2014 Fertility Associates of Memphis ... Bank USA , a network of more than 20 ... partnership, patients have fast access to a national pool ... IVF . Fertility Associates of Memphis is the only ... treatment option. , Dr. William Kutteh , director ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one ... of Nick Maroulis, Pharm.D. to the newly created position ... In this position, Dr. Maroulis will continue to manage ... of our multi-site pharmacies as the company expands. Dr. ... that time he has served in many different capacities ...
(Date:12/19/2014)... Dec. 19, 2014 Bina Technologies, Inc. (Bina, ... that they have been acquired by Roche (SIX: RO, ... privately held company that provides a big data platform ... (NGS) data for the academic and translational research markets. ... and will continue to focus on development of their ...
Breaking Biology Technology:WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... Aligns Operations for Enhanced Performance, DECATUR, ... (NYSE: ADM ) chairman, chief executive ... organizational restructure of the,Company, designed to enhance ... responsibility for long-term success. The reorganization creates ...
... oximetry technology to significantly reduce, false alarms without missing ... ... Aug. 22 Masimo (Nasdaq:,MASI), the inventor of Pulse CO-Oximetry ... partnership with Apria,Healthcare to provide pulse oximetry products and accessories ...
... symbol: SBS, - Canadian Biotechnology Company confirms commercial ... AI Milano variant and clarifies status of native ... - SemBioSys Genetics Inc.,(TSX:SBS), a biotechnology company developing ... diseases, today updated a release,issued on July 12, ...
Cached Biology Technology:ADM Reorganizes Operations 2ADM Reorganizes Operations 3ADM Reorganizes Operations 4Apria Healthcare Chooses Masimo SET Pulse Oximetry for Use in the Company's Home Health Care Business 2Apria Healthcare Chooses Masimo SET Pulse Oximetry for Use in the Company's Home Health Care Business 3SemBioSys updates Apo AI development program 2SemBioSys updates Apo AI development program 3SemBioSys updates Apo AI development program 4
(Date:12/11/2014)... 2014  That blood pressure plays a role in human ... the medical term for high blood pressure – was first ... inflatable cuff that,s used in measuring blood pressure was invented ... new about hypertension, its triggers and its effects. In fact, ... and the best ways to treat it. For ...
(Date:12/10/2014)... 9, 2014  Valencell, a leader in performance biometric ... staggering demand from its licensees for highly accurate, clinically ... not solely coming from fitness and health sectors, but ... "A wearable is only as useful as the biometric ... ultimate driver in long-term mass consumer adoption of wearable ...
(Date:12/10/2014)... Research and Markets ( http://www.researchandmarkets.com/research/xclcvw/biometrics_market ... "Biometrics Market in Japan 2014-2018" report to ... The integration of biometrics and ... and upgradation of the driver,s license is one ... Besides the aforementioned projects, biometrics is being used ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wearable Technology Products Demand Highly Accurate Biometric Technology 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
... sole proprietors of their nests, some tropical species time ... a 150-year-old evolutionary mystery, says Queens University Biology professor ... confirms one of Charles Darwins more controversial theories ... many experts that different species can arise, unhindered, ...
... The Shifting Baselines Toolset is presented to the public and ... , When: Public symposium 1pm to 5:15pm, Wednesday 14th November ... city campus. , The meeting will be launched with a ... for interviews on the 14th and on other days by ...
... 13, 2007) A major study that will provide a ... be conducted by the La Jolla Institute for Allergy ... The five-year study, funded by the National Institute ... National Institutes of Health, could lead to revolutionary new ...
Cached Biology News:'Time-sharing' tropical birds key to evolutionary mystery 2How much fish have we got? 2How much fish have we got? 3NIH selects LIAI for major study on allergy molecular causes and possible treatments 2NIH selects LIAI for major study on allergy molecular causes and possible treatments 3NIH selects LIAI for major study on allergy molecular causes and possible treatments 4
Goat polyclonal to SART3 ( Abpromise for all tested applications). Antigen: Synthetic peptide: MSNADFAKLFLRK, corresponding to C terminal amino acids 951-963 of Human SART3 Entrez Gene ID: 9...
JAB1 Immunogen: Synthetic peptide, conjugated to KLH, corresponding to residues S(201) E Y Q T I P L N K I E D F G V(216) of human JAB1. The sequence is identical in mouse and rat. Storage: -...
Hamartin/TSC1 (1B2) Mouse mAb Ship: Hot Store: -20 C...
Blank Calibration Particles, 3.0-3.4 mu m 5 ml...
Biology Products: